Contraception
Volume 81, Issue 5 , Pages 401-407 , May 2010

Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation “pill scare”

Received 8 September 2009 ,Revised 16 December 2009 ,Accepted 16 December 2009.

References 

  1. Darney PD. The androgenicity of progestins. Am J Med. 1995;98:104S–110S
  2. World Health Organization . Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;346:1582–1588
  3. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP, Enhancement by factor V. Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet. 1995;346:1593–1596
  4. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995;346:1589–1593
  5. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ. 1996;312:83–88
  6. Edwards RG, Cohen J. Reproductive choices in 2000: the relative safety of current oral contraceptives. Hum Reprod Update. 1999;5:563–564
  7. Heinemann LA. The changing scene–an unnecessary pill crisis. Hum Reprod Update. 1999;5:746–755
  8. Heinemann LA, Lewis MA, Assmann A, Thiel C. Case-control studies on venous thromboembolism: bias due to design? A methodological study on venous thromboembolism and steroid hormone use. Contraception. 2002;65:207–214
  9. Lewis MA. The epidemiology of oral contraceptive use: a critical review of the studies on oral contraceptives and the health of young women. Am J Obstet Gynecol. 1998;179:1086–1097
  10. Lewis MA, MacRae KD, Kuhl-Habichl D, Bruppacher R, Heinemann LA, Spitzer WO. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod. 1999;14:1493–1499
  11. Heinemann LA, Garbe E. Fertility control: update and trends. In:  Rabe T,  Runnebaum B editor. Cardiovascular risks of oral hormonal contraception. Heidelberg: Springer; 1998;p. 91–119
  12. Heinemann LA, Garbe E, Farmer R, Lewis MA. Venous thromboembolism and oral contraceptive use: a methodological study of diagnostic suspicion and referral bias. Eur J Contracept Reprod Health Care. 2000;5:183–191
  13. Bounameaux H, Reber-Wasem MA. Superficial thrombophlebitis and deep vein thrombosis. A controversial association. Arch Intern Med. 1997;157:1822–1824
  14. Spitzer WO, Thorogood M, Heinemann LA. Trinational case-control study of oral contraceptives and health. Pharmacoepidemiol Drug Saf. 1993;2:21–31
  15. Heinemann LA, Dinger J. Safety of a new oral contraceptive containing drospirenone. Drug Saf. 2004;27:1001–1018
  16. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007;75:344–354
  17. Mr Justice MacKay. Judgement in the Court Case at Royal Courts of Justice London, 2002: XYZ and others & Schering Healthcare Ltd, Organon Laboratories Ltd. and John Wyeth and Brother Ltd. High Court of Justice, London, 29 July 2002, EWHC 1420 (QB). [cited 2009 8 July]; Available from: http://www.hmcourts-service.gov.uk/judgmentsfiles/j1298/xyz_-v-schering.htm.
  18. Schwarz T, Siegert G, Oettler W, et al. Venous thrombosis after long-haul flights. Arch Intern Med. 2003;163:2759–2764

☆ Competing interest: This study was sponsored by an unconditional grant from Bayer Schering Pharma, a leading manufacturer of oral contraceptives, including those containing gestodene.

☆☆ Authors' contributions: L.A.J.H. was responsible for the design of the study, prepared the data analysis plan, ran the analyses and drafted the manuscript; JCD contributed to writing and revising the manuscript and was involved in the data analysis; A.A. was responsible for the development of all questionnaires, contributed to organizing the field work and quality checks, and contributed to the manuscript; T.D.M. was responsible for final data management, involved in the data analyses and contributed to the manuscript.

PII: S0010-7824(09)00540-X

doi: 10.1016/j.contraception.2009.12.014

Contraception
Volume 81, Issue 5 , Pages 401-407 , May 2010

Article Tools